Menin inhibitor maintenance therapy after stem cell transplant
Part of Blood & lymphatic, Cancer clinical trials.
This study tracks how well a newer drug class (menin inhibitors) works to prevent acute leukemia from coming back after a stem cell transplant. You would be observed for safety and effectiveness if you're already taking one of these drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 15 or older
- Diagnosed with acute leukemia (AML, ALL, or MPAL) with specific genetic mutations (NPM1, KMT2A, or NUP98)
- Already completed a stem cell transplant at least 30 days ago
- Already taken a menin inhibitor for at least 2 weeks and are doing well (no leukemia relapse)
- No uncontrolled infections, severe organ damage, or severe graft-versus-host disease
- Can take oral medication by mouth without absorption problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BN104 to help keep leukemia from coming back after a stem cell transplant. It's for people with certain types of acute leukemia that have specific gene changes.
This trial tests if the drug ziftomenib can help prevent AML from coming back after a stem cell transplant. It is for people who have certain gene changes (KMT2A rearrangement or NPM1 mutation) and are in remission or near-remission before transplant.
This trial tests different maintenance therapies based on the specific gene mutations in your leukemia or MDS after a stem cell transplant. Your doctor will choose the right drug for your mutation type to help keep the cancer from coming back.
This clinical trial tests a new menin-blocking drug called BN104 in combination with chemotherapy or other targeted drugs for people with acute myeloid leukemia (AML) that has certain genetic changes. It may be an option if your AML is newly diagnosed or if you've already tried a menin inhibitor and it didn't work well enough.
This trial tests whether taking avapritinib (a targeted pill) after a stem cell transplant can help keep leukemia in remission for people whose AML has a KIT mutation. It's a maintenance therapy meant to prevent relapse.
This trial tests whether a maintenance treatment with a hypomethylating agent can help keep favorable-risk acute myeloid leukemia (AML) patients in remission after they have completed initial therapy. It is designed for patients who have achieved negative minimal residual disease (MRD) and have not received a stem cell transplant.
Hear when a new Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.